Baxter International Inc. reported third-quarter 2025 results with worldwide sales from continuing operations totaling approximately $2.8 billion, representing a 5% increase on a reported basis and a 2% increase on an operational basis. U.S. sales from continuing operations reached about $1.5 billion, reflecting a 3% increase on a reported basis and a 1% decline on an operational basis. International sales from continuing operations were approximately $1.3 billion, up 8% on a reported basis and 5% on an operational basis. On a U.S. GAAP basis, net income (loss) from continuing operations was ($51) million, or ($0.10) per diluted share. On an adjusted basis, net income from continuing operations was $0.69 per diluted share, increasing 41% compared to the prior year. Pharmaceuticals sales in the third quarter totaled approximately $632 million, an increase of 7% on both a reported and operational basis. The segment performance was driven by growth in Drug Compounding and Injectables & Anesthesia products, with increased volumes in select international markets and steady contributions from the Injectables portfolio. During the period, Baxter launched the Welch Allyn Connex 360 Vital Signs Monitor, its latest patient monitoring device, with advanced connectivity, security, and upgrade capabilities. The company's Kidney Care business was acquired by Carlyle in January 2025 and is reported as discontinued operations.